Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Multinational Study of the Effects of Fabrazyme (Agalsidase Beta) Treatment on Lactation and Infants

NCT00230607 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT00230607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00230607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Multinational Study of the Effects of Fabrazyme (Agalsidase Beta) Treatment on Lactation and Infants
Lead sponsor
Genzyme, a Sanofi Company
Phase
Phase 4
Overall status
Terminated
Start date
May 28, 2006
Completion date
February 9, 2024
Enrollment
7 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

alpha galactosidase a deficiency, fabry disease